Teva Pharmaceutical Industries Limited (NYSE:TEVA) Short Interest Up 25.1% in March

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 34,800,000 shares, an increase of 25.1% from the February 28th total of 27,810,000 shares. Based on an average daily volume of 12,260,000 shares, the short-interest ratio is presently 2.8 days. Approximately 3.1% of the shares of the stock are short sold.

Teva Pharmaceutical Industries Price Performance

TEVA traded down $0.09 during midday trading on Tuesday, hitting $15.28. The stock had a trading volume of 8,287,196 shares, compared to its average volume of 9,683,731. The company has a market cap of $17.33 billion, a P/E ratio of -10.54, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries has a 1 year low of $12.51 and a 1 year high of $22.80. The business has a fifty day moving average of $17.08 and a 200 day moving average of $18.11. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently added to or reduced their stakes in TEVA. Oarsman Capital Inc. bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $44,000. Wilmington Savings Fund Society FSB purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $50,000. Ameliora Wealth Management Ltd. bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $66,000. Finally, IFP Advisors Inc increased its stake in shares of Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after buying an additional 1,960 shares during the period. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on TEVA shares. Piper Sandler increased their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Barclays decreased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. Bank of America lowered their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Finally, StockNews.com lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday, March 27th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.